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Background & Aims: To assess the possible association between a validated Dietary 43 
Inflammatory Index (DII) and specific dietary components with suitable non-invasive markers 44 
of liver status in overweight and obese subjects within the PREDIMED study. 45 
Methods: A cross-sectional study encompassing 794 randomized overweight and obese 46 
participants (mean ± SD age: 67.0 ± 5.0 y, 55% females) from the PREDIMED (PREvención 47 
con DIeta MEDiterránea) trial was conducted. DII is a validated tool evaluating the effect of 48 
diet on six inflammatory biomarkers (IL-1b, IL-4, IL-6, IL-10, TNF-α and C-reactive 49 
protein). Furthermore, a validated 137-item food-frequency-questionnaire was used to obtain 50 
the information about the food intake. In addition, anthropometric measurements and several 51 
non-invasive markers of liver status were assessed and the Fatty Liver Index (FLI) score was 52 
calculated.  53 
Results: A higher DII and lower adherence to Mediterranean diet (MeDiet) were associated 54 
with a higher degree of liver damage (FLI>60) in obese as compared to overweight 55 
participants. Furthermore, the DII score was positively associated with relevant non-invasive 56 
liver markers (ALT, AST, GGT and FLI) and directly affected FLI values. Interestingly, a 57 
positive correlation was observed between liver damage (>50th percentile FLI) and nutrients 58 
and foods linked to a pro-inflammatory dietary pattern. 59 
Conclusions: This study reinforced the concept that obesity is associated with liver damage 60 
and revealed that the consumption of a pro-inflammatory dietary pattern might contribute to 61 
obesity and fatty liver disease features. These data suggest that a well-designed precision diet 62 
including putative anti-inflammatory components could specifically prevent and ameliorate 63 
non-alcoholic fatty liver manifestations in addition to obesity. 64 
 65 
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INTRODUCTION 67 
Non-alcoholic fatty liver disease (NAFLD) is a condition of excessive hepatic lipid accumulation 68 
in subjects that consume less than 20g ethanol per day, without other known causes such as 69 
drugs prescription or exposure to toxins (1). In developed countries, NAFLD affects 70 
approximately 20-30% in the general adult population. The term NAFLD encompasses a range 71 
of conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), which 72 
eventually can lead to cirrhosis and, in some cases, hepatocellular carcinoma (1). Liver biopsy 73 
is considered the “gold standard” of steatosis, fibrosis and cirrhosis. However, it is rarely 74 
performed because it is an invasive procedure with a significant degree of sampling error; 75 
therefore, investigators and clinicians are focusing on the design and application of non-76 
invasive liver damage markers and scores for diagnosis (2). 77 
NAFLD has been related with obesity, insulin resistance, hypertension and dyslipidemia, and 78 
it is regarded as a key liver manifestation of the metabolic syndrome (3). In fact, excessive 79 
body mass index (BMI kg/m2) and visceral fat (%) are known to be important risk factors in 80 
NAFLD onset and at least two-thirds of population with obesity and diabetes show hepatic 81 
steatosis (4). In addition, inflammation has been hypothesized as an underlying mechanism in 82 
the link between obesity and NAFLD. The pathogenesis of NAFLD is multifactorial and 83 
denoted by environmental factors such as unbalanced diets and overnutrition as well as by 84 
lack of physical activity in the context of a genetic predisposition (5, 6). Currently, the 85 
treatment of NAFLD is founded on diet and lifestyle modifications (7). Weight lowering, 86 
exercise and healthy eating habits are the main tools to fight NAFLD (8). Nevertheless, there is 87 
no a specifically characterized dietary pattern and further studies are needed (9). Moreover, 88 
because not all overweight individuals develop NAFLD, it is unknown if specific dietary 89 
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patterns may prevent or protect against the development of NAFLD  overweight or obese 90 
subjects. For this reason, more information about the interplay between diet and fatty liver, 91 
taking into account inflammation as an implicated mechanism, is required to design effective 92 
strategies in the prevention and treatment of obesity-associated NAFLD. 93 
In this context, the current study investigated associations of a validated DII, recognized as a 94 
tool for assessing the inflammatory capacity of the diet according to six inflammatory 95 
biomarkers (IL-1b, IL-4, IL-6, IL-10, TNF-α and C-reactive protein (CRP)), with non-96 
invasive liver markers in overweight and obese subjects within the PREDIMED study. 97 
 98 
METHODS 99 
The ‘PREDIMED’ study was a parallel-group, multi-centre, clinical trial targeting the 100 
primary prevention of Cardiovascular Disease (CVD) via the MeDiet 101 
(http://www.predimed.com). A description of the study design has been previously published 102 
(10, 11). This research was registered as an International Standard Randomized Controlled 103 
Trial, number ISRCTN355739639. Men aged 55–80 years and women aged 60–80 years were 104 
enrolled by eleven centres in Spain between October 2003 and December 2010. Eligible 105 
participants had no previous CVD event, but were at high CVD risk at baseline due to the 106 
diagnosis of type 2 diabetes mellitus or the presence of at least three of the following major 107 
cardiovascular risk factors: smoking (more than one cigarette per d during the last month); 108 
elevated blood pressure (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 109 
mmHg or antihypertensive medication); high LDL-cholesterol levels (≥160 mg/dl); low HDL-110 
cholesterol levels (<40 mg/dl in men or <50 mg/dl in women, independently of lipid-lowering 111 
therapy); BMI ≥ 25.0 kg/m2; or family history of premature Chronic Heart Disease (CHD. 112 
Fasting blood samples were collected and trained dietitians assisted participants in completing 113 
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a validated Food Frequency Questionnaire including 137 food-items (FFQ). As previously 114 
described (12), an ad hoc computer program was created using the information available from 115 
validated standard Spanish food composition tables (13) to translate food consumption 116 
obtained from FFQ into nutrients (macronutrients and micronutrients) and energy. 117 
Furthermore, participants completed the Minnesota physical activity questionnaire validated 118 
for Spanish-language (14) and adherence to the MeDiet was assessed using a fourteen-item 119 
dietary screen (≥ 9 points from the Mediterranean test) as described elsewhere (15). A total of 120 
794 randomized subjects from the PREDIMED trial were included in the present study to 121 
evaluate the DII with respect to liver status at baseline. For some analyses, the subjects were 122 
categorized depending on adiposity level and according with the Spanish Association for the 123 
Study of Obesity (16) as (BMI ≤ 26.9 kg/m2; BMI > 27.0 - ≤ 29.9 kg/m2; BMI ≥ 30.0 kg/m2). 124 
Dietary Inflammatory Index 125 
The DII is a scoring algorithm that evaluates the effect of diet on six inflammatory 126 
biomarkers; IL-1β, IL-4, IL-6, IL-10, TNF-α, and CRP. In the present study, habitual dietary 127 
intake of each participant was derived from a 137-item FFQ, which has been validated in 128 
Spain (12), and has been extensively used in Mediterranean studies of nutritional 129 
epidemiology. Dietary intake data achieve by this FFQ was then used in the estimation of DII 130 
at baseline (17, 18). The DII was calculated as described previously (19, 20). Briefly, dietary 131 
parameters were scored according to their effect (pro-inflammatory, anti-inflammatory, or no 132 
effect) on six well-established inflammatory biomarkers (IL-1b, IL-4, IL-6, IL-10, TNF-α and 133 
CRP). An inflammatory effect score was computed for every food and standardized to a 134 
composite database representative of food consumption patterns of a diverse population. 135 
Inflammatory effect scores for each food were converted to food parameter specific DII 136 
scores, which were then summed to obtain an overall DII score for each participant.  Positive 137 
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values represent a pro-inflammatory diet, whereas negative values represent an anti-138 
inflammatory diet. DII scores range from 7.98 (maximally pro-inflammatory) to -8.87 139 
(maximally anti-inflammatory), as reported elsewhere (21). 140 
 141 
Fatty Liver Index 142 
The FLI score was designed after a bootstrapped stepwise logistic regression analysis (22). 143 
Out of thirteen variables (including gender, age, ethanol intake, ALT, AST, GGT, BMI, Waist 144 
Circumference (WC), sum of four skinfolds, glucose, insulin, Triglycerides (TG) and 145 
cholesterol) four predictors remained within the equation:  146 
FLI = [e 0.953*log[e] [triglycerides] + 0.139*BMI + 0.718*log[e] (GGT) + 0.053*waist 147 
circumference - 15.745] / [1 + e 0.953*log[e] [triglycerides] + 0.139*BMI + 0.718*log[e]  148 
[GGT] + 0.053*waist circumference - 15.745] * 100 149 
The FLI ranges from 0 to 100. Thus. FLI scores of <30 and FLI ≥ 60 indicated the absence or 150 
presence, respectively, in fatty liver with a good diagnostic accuracy (22). 151 
 152 
Statistical analysis 153 
Normality distributions of the analyzed variables were assessed according to the Shapiro–154 
Wilk test. Statistical analyses were stratified by BMI in order to consider overweight and 155 
obesity (BMI ≥ 30 kg/m2) categories. Continuous variables (total energy intake, Metabolic 156 
Equivalent of Task (METs), DII, FLI, alcohol intake, nutrient and food consumption) were 157 
compared between groups by the Student’s t-test or the Mann–Whitney U test for parametric 158 
or non-parametric variables, respectively. Intakes of carbohydrate, protein and fat (also fat 159 
subtypes) were expressed as percentage of total energy intake. Categorical variables were 160 
compared by the chi-squared test and are defined as High Adherence to the MedDiet (High 161 
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adherence) ≥ 9, smoking habit (never: no smoking habit; former: >5 years gave up smoking; 162 
current smoker: at least 1 cigarette/day).  163 
Two new groups were defined considering the median of the FLI score as the cut off (< 50th 164 
percentile FLI vs ≥ 50th percentile FLI) and a new analysis considering these two groups was 165 
carried out using the tests described before.  166 
The relationship between anthropometric measurements, dietary factors and NAFLD 167 
biomarkers was assessed by means of Pearson and Sperman´s correlation tests for parametric 168 
and non-parametric variables, respectively. Variables associated with NAFLD biomarkers 169 
were selected to be included in a linear regression model.  Thus, a linear regression model 170 
was set up to find out the influence of independent variables such as DII, and anthropometric 171 
and biochemical parameters on the variability of the FLI score. Analyses were performed 172 
using STATA version 12.0 (Stata Corp). All p-values are two-tailed, and differences were 173 
considered statistically significant at p<0.05. 174 
 175 
RESULTS 176 
At baseline, the average age of participants was 67 years old, of which 55% were women and 177 
only 12% were current smokers. Also, the main characteristics of the participants according to 178 
phenotype, quality of the diet and dietary consumption are reported (Table 1). The analysis of 179 
the dietary pattern according to main groups evidenced that polyunsaturated fat, Ω3 fatty 180 
acids (long-chain n-3 polyunsaturated fatty acids), Ω6, vitamin E and D, dairy and total 181 
energy intake were higher (p<0.05) in subjects with BMI ≤ 26.9 kg/m2, while red meat 182 
consumption was higher in obese participants (Table 1). Differences in the adherence to the 183 
Mediterranean diet (p<0.001) were observed, and individuals with obesity showed lower 184 
adherence. Interestingly, a higher DII (p<0.001) was also found in obese participants (Figure 185 
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1). In addition, DII was negatively correlated with MeDiet adherence (r= -0.263; p<0.001). 186 
Liver-related markers (Table 2) particularly FLI and TG, were higher in the obese group 187 
(p<0.0011). Furthermore, individuals were classified according to the median value of FLI 188 
and food consumption was explored (Table 3). All nutrients showed significant differences 189 
with model 2 of Ancova Test except for diet carbonated drinks. 190 
The consumption of carbohydrate, fiber, PUFA, fruits, vegetables, dairy, animal protein, fish, 191 
nuts, omega-3, omega-6, linoleic acid, Vit. B1, Vit. B6, Vit. B2, Vit. C, Vit. D, Vit. B9, Na, k, 192 
Mg, P, Ca, betacarotens, phytoesterols were higher in patients with the lowest FLI scores. In 193 
addition, the anti-inflammatory pattern measured by DII was lower in these individuals (≤ p50 194 
FLI). In order to further evaluate these results several correlations analyses were carried out. 195 
Fiber, protein (%E), vegetables, fruits, dairy, semi-skimmed milk, fresh cheese, fatty fish, 196 
nuts, Ω 3 marine, Vit.B6, Vit.B2, Vit.C, Vit. D, Vit. B9, K, Mg, P, Ca, betacarotens were 197 
negatively correlated with FLI (Figure 2). However, red meat and sugar showed a positive, 198 
significant relationship. Interestingly, the DII score was positively associated (p<0.001) with 199 
non-invasive liver markers (ALT, AST, GGT and FLI) (Figure 3). A linear regression 200 
analysis was carried out to assess the influence that some factors might have on FLI. 201 
Variables were independently studied by univariable linear regression. Thus, variables 202 
associated with the FLI were: DII (β= 2.02, R= 0.019, p<0.001), age (β= -0.54, R= 0.020, 203 
p<0.001), Total energy intake (β= 0.0004, R= 0.619, p<0.001), Gender (β= -4.67, R=0.003, 204 
p= 0.010), ALT (U/L) (β= 0.32, R=0.038, p<0.001), METs (β= -0.46, R= 0.006, p= 0.011). 205 
When these variables were jointly considered, the predictors of the model explained up to 206 
9.2% (Table 4) of the variation of the FLI (adjusted R2 = 0.099, Pmodel <0.001).  207 
 208 
 209 
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DISCUSSION 210 
The DII is a relatively novel tool for evaluating the inflammatory potential of a diet that 211 
reflects both a robust scientific framework and standardization of individual intakes to global 212 
referent values (23). Results based on this index indicate that it reliably predicts 213 
concentrations of inflammatory markers, such as C-reactive protein, IL-6 (21, 23-25). In the 214 
present study, a higher pro-inflammatory diet was observed in participants with higher BMI, 215 
suggesting that diet-induced inflammation may increase or maintain obesity, particularly 216 
central obesity, in an overweight or obese population with high WC values. Indeed, 217 
inflammation is induced by adiposity (26, 27), but this relationship can be bidirectional. Thus, 218 
a pro-inflammatory diet can increase obesity and accompanying comorbidities in liver, 219 
triggering a continuous cycle. These findings support the idea that overall dietary patterns 220 
play an essential role in the metabolism of inflammation process (28). Remarkably, a previous 221 
ancillary study carried out within of the PREDIMED trial showed that the DII was inversely 222 
associated with the adherence to a MeDiet and healthy foods consumption (25). Other trials 223 
have also evidenced correlations of specific nutrients such as total dietary fiber intake (29), 224 
vitamin E and C intake (30) and antioxidants with lower levels of inflammatory markers (31, 225 
32). Furthermore, one analysis reported the anti-inflammatory capacity of the MeDiet (33-35). 226 
Moreover, a number of trials have reported the association between specific dietary anti-227 
inflammatory components and better liver status, suggesting that the prevalence or incidence 228 
of NAFLD might be mediated through different inflammatory pathways where food play a 229 
key role, but not as a whole. 230 
The liver is the principal location of amino acid synthesis, protein degradation, carbohydrate 231 
metabolism, cholesterol synthesis, the production of TG and the bulk of lipoprotein synthesis, 232 
as well as several other regulatory and growth factors (36). Thus, fatty liver is not only 233 
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considered hepatic manifestation of metabolic syndrome, but it could also promote the 234 
emerging metabolic-related extra-hepatic complications (37-39). Currently, there are no 235 
effective therapies available for the treatment of NAFLD. Recent investigations have focused 236 
on identifying biomarkers to predict NASH or NAFLD. However, these strategies have rarely 237 
benefited clinical practice in terms of NAFLD diagnosis or discrimination of the pathological 238 
evolution of NAFLD. Therefore, the development of current non-invasive evaluations of 239 
NAFLD could be useful for the diagnosis of fatty liver (40). In this context, Bedogni et al. 240 
developed a simple scoring system called FLI which considers TG, GGT, BMI, and WC and 241 
is easily calculated (41). FLI was developed for the prediction of fatty liver disease evidenced 242 
a good area under the curve of 0.84. Thus, FLI accuracy has been validated in comparison 243 
with liver ultrasonography (22). Also, WC and TG have been used to predict the presence of 244 
liver fibrosis in a clinical study in children (42). In addition, BMI and GGT have been 245 
reported as independent predictors of fatty liver in other research studies (43, 44). Regarding 246 
the relationship between diet and the FLI, significant differences were observed when 247 
stratified based on the median value of the FLI. However, there is no a well characterized 248 
dietary pattern for fatty liver disease patients and further randomized controlled trials are 249 
needed (45). In the present study, different dietary patterns were found. First, patients with 250 
less fatty liver consumed more animal protein from white meat and fish. In contrast, the 251 
consumption of red meat was higher in patients with high FLI. These results are reinforced by 252 
a study of Freedman et al, (2010) where the authors found that red meat may be associated 253 
with increased chronic liver disease, whereas white meat may be associated with reduced risk 254 
(46). Another controversial finding is emphasized in the dairy group. All dairy food showed a 255 
negative relationship with fatty liver, with the exception of cheeses high in fat, which 256 
increased fatty liver. One study from the EPIC-cohort suggests that elevated consumption of 257 
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dairy products, specifically milk and cheese, can be associated with increased liver diseases 258 
(47). In contrast, another study reported that three low-fat-dairy servings per day ameliorated 259 
both inflammation and liver function in metabolic syndrome subjects (48). In addition, the 260 
consumption of cereals and potatoes showed a positive correlation with FLI, which contrasts 261 
with the study of Shi L et al., (2012), where authors found that people with NAFLD 262 
consumed a reduced quantity of potatoes and cereals compared to the control group (49). 263 
Another research disclosed the consumption of cereals in general increased the likelihood of 264 
having NAFLD (50) . Surprisingly, a positive correlation with the consumption of legumes 265 
was noted, but not statistically significant. Legumes are known as a healthy food and most 266 
food studies classify legumes as a pattern of a healthy and anti-inflammatory diet (51, 52). In 267 
contrast, in a multicenter study from India, the high-legume consumption did not reveal 268 
association with obesity and metabolic-related comorbidities (53). Taking into account these 269 
results, a higher consumption of all antioxidants, flavonoids, healthy fatty acids were 270 
inversely related with FLI. These results are consistent with a recent review, which found that 271 
flavonoids and an antioxidant components had beneficial effects in patients with NAFLD 272 
(54).  273 
 274 
LIMITATIONS 275 
Our study is a transversal design, which identifies associations; however, these studies are 276 
remarkably similar to those from Randomized Control trials on the same topic (55). A large 277 
cross-sectional study such as this one contributes to the design of new dietary patterns in 278 
NAFLD pathology and to establishing new hypotheses for large prospective studies and 279 
clinical trials. One limitation of this study is that liver fat was not directly measured, i.e 280 
magnetic resonance spectroscopy (MRS) or magnetic resonance imaging (MRI). Another 281 
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limitation is the lack of a control group comprised of exclusively normoweight subjects due 282 
to the inclusion criteria requirements for PREDIMED study participants. Lastly, the FFQ are 283 
known to contain a certain degree of measurement error, which might affect results that 284 
depend on such evaluation. However, validity of the FFQ used in our cohort has been 285 
evaluated, showing good association with nutrient intake according to repeated food records 286 
(14). In addition, the participants were from a Mediterranean area and had a high risk of 287 
cardiovascular disease, which could limit the generalizability of our findings to different 288 
settings. 289 
 290 
CONCLUSION  291 
To our knowledge, this is the first study evaluating the association between DII and liver 292 
status in overweight and obese subjects. Participants with higher liver damage (FLI) and 293 
adiposity (BMI ≥ 30kg/m2) showed a pro-inflammatory dietary pattern (DII) and worse 294 
adherence to the MeDiet. In addition, the DII score was positively associated with non-295 
invasive liver damage markers. These findings suggest that the consumption of an anti-296 
inflammatory dietary pattern might contribute the reduction of obesity and related co-297 
morbidities, especially NAFLD following precision nutrition guidelines.  298 
 299 
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Table 1. Description of the phenotypic characteristics, quality of the diet, nutrient and food consumption in 
PREDIMED Trial. 
 
≤ 26.9  
kg/m2 
≥ 27 -  <29.9 
kg/m2 
≥ 30 
kg/m2 
p 
n=794 n= 182  n= 235 n=377  
Phenotypic characteristics     
   Waist Circumference (cm) 93 (6) 99 (6)# 106 (7)*ϯ <0.001 
   Diabetes (%) 58 54 51 0.228 
   Hypercholesterolemia (%) 63 68 70 0.267 
   Hypertension (%) 78 84 87* 0.015 
Quality of the diet     
   Dietary Inflammatory Index -0.8 (1) -0.6 (1) -0.1 (1)* 0.003 
   High Adherence to MedDiet (n) 52 53 38*ϯ <0.001 
Energy and Macronutrients     
   Total energy intake (Kcal/d) 2384 (575) 2349 (611) 2279 (582) 0.109 
   Carbohydrate (%E) 39 (6) 39 (6) 40 (6) 0.086 
   Total Protein (%E) 16 (2) 16 (2) 16 (2) 0.055 
     Animal (%E) 67 (6) 67 (7) 68 (7) 0.089 
 Vegetable (%E) 32 (6) 32 (7) 31 (7) 0.263 
   Lipid(%E) 41 (6) 41 (6) 40 (6) 0.516 
 Saturated Fat (g/d) 28 (9) 27 (9) 27 (9) 0.386 
 Monounsaturated fat (g/d) 54 (15) 53 (17) 51 (15) 0.210 
 Polyunsaturated fat (g/d) 17 (6) 17 (6) 16 (5)* 0.007 
     Marine Ω3 (g/d) 0.8 (0.5) 0.7 (0.4) 0.7 (0.4)* 0.024 
     No marine Ω3 (g/d) 1.6 (0.6) 1.5 (0.6) 1.4 (0.5)* 0.002 
     Ω 6 (g/d) 14 (5) 14 (5) 13 (5)* 0.016 
Micronutrients     
   Fibre (g/d) 24 (8) 23 (7) 23(7) 0.223 
   Vitamin E (µg /d) 10 (3) 10 (3) 9 (3) 0.046 
   Vitamin D (µg /d) 6 (3) 5 (3) 5 (3) 0.019 
   Vitamin A (µg /d) 1324 (854) 1303 (1019) 1292 (942) 0.931 
   Vitamin C (µg /d) 184 (79) 178 (74) 179 (75) 0.672 
   Alcohol intake (g/d) 8 (11) 9 (15) 7 (12) 0.208 
Food groups     
   Vegetables (g/d) 322 (136) 312 (133) 297 (131) 0.100 
   Fruits (g/d) 310 (168) 315 (178) 310 (172) 0.947 
   Legumes (g/d) 17 (8) 17 (8) 18 (8) 0.820 
   Cereals (without potato) (g/d) 150 (87) 148 (8) 148 (78) 0.940 
   Potato (g/d) 107 (48) 101 (45) 101 (45)   0.298 
   Dairy products (g/d) 401 (232) 376 (217) 352 (194)* 0.035 
   Whole milk (g/d) 36 (126) 41 (114) 33 (95) 0.700 
   Semi-skimmed milk (g/d) 138 (205) 125 (184) 119 (165) 0.499 
   Skimmed milk (g/d) 96 (170) 90 (167) 76 (138) 0.291 
   Meat (g/d) 145 (55) 138 (57) 149 (60) 0.089 
  Red meat (g/d) 85 (43) 80 (44) 89 (48) 0.087 
  White meat (g/d) 60 (32) 57 (33) 60 (32) 0.664 
   Fish (g/d) 107 (47) 99 (42) 101 (43) 0.223 
   Virgin Olive oil (g/d) 41 (17) 41 (18) 41 (17) 0.958 
 
Continuous variables are shown as means (SDs), and categorical variables are shown as percentages.  
MedDiet, Mediterranean Diet; PREDIMED, PREvención con DIeta MEDiterránea. 
 p<0.05 was considered statistically significance.  
*p was significant between participants with BMI ≤ 26.9 Kg/m2 and BMI ≥ 30 kg/m2 
ϯ p was significant between participants with BMI ≥ 27 - <29.9 kg/m2 and BMI ≥ 30 kg/m2 
# p was significant between participants with BMI ≤ 26.9 kg/m2 and ≥ 27 - <29.9 kg/m2 
 
Table 2 Liver markers and Fatty Liver Index in the PREDIMED trial (n= 794). 
 ≤ 26.9 kg/m
2 
n=182 
≥ 27.0 - <29.9 kg/m2 
       n=235 
≥ 30 kg/m2 
n= 377
 
p 
TG (mg/dl)  119 (70)    130 (67) 143 (72)* <0.001 
ALT(UI/L)  22 (15) 23 (16) 23 (10) 0.405 
AST (UI/L)  21 (7) 20 (6) 21 (12) 0.574 
AST/ALT  1 (0.3) 1 (0.6) 0.9 (0.5) 0.167 
GGT (UI/L)  32 (559 29 (26) 29 (23) 0.562 
FLI  37 (18) 56 (17) 76 (14)* <0.001 
All variables are shown as means ± SD. AST, Aspartate Aminotransferase. ALT,  
Alanine Aminotransferase. GGT, Gamma-Glutamyltransferase. FLI, Fatty Liver Index. 
 p<0.05 was considered statistically significance.  
*p was significant between participants with BMI ≤ 26.9 Kg/m2 and BMI ≥ 30.0 kg/m2 
 
 
 
 
 Table 3 Nutrients and food consumption (mean and SD) according to FLI in 
PREDIMED trial (n = 794). 
    Fatty Liver Index   
n=794 ≤FLI P50 >FLI P50 Panova1 Panova2 Correlation with FLI (p) 
Macronutrients      
Carbohydrate (%E) 40 (3) 39 (0.3) 0.056 <0.001 -0.01 (0.651) 
   Dietary fiber (g) 24 (8) 22 (7) 0.003 <0.001 -0.10 (0.004) 
Protein (%E) 16 (0.1) 16 (0.1) <0.001 <0.001 -0.11 (0.001) 
   Animal protein (g) 65 (17) 64 (17) 0.003 <0.001 -0.05 (0.111) 
   Vegetal protein (g) 30 (9) 30 (9) <0.001 <0.001 -0.03 (0.297) 
Lipids (%E) 40 (0.3) 41 (0.2) 0.222 <0.001 0.08 (0.807) 
   PUFA (g) 17 (6) 16 (5) <0.001 <0.001 -0.02 (0.570) 
   MUFA (g) 52 (16) 53 (16) <0.001 <0.001 0.03 (0.270) 
   SFA (g) 27 (9) 27 (9) <0.001 <0.001 0.02 (0.406) 
Food groups      
Vegetables (g/d) 324 (6) 291 (6) <0.001 <0.001 -0.11 (0.001) 
Fruits (g/d) 324 (8.9) 299 (8.3) 0.197 <0.001 -0.06 (0.071) 
Cereals (without potato) (g/d) 144 (4) 153 (4) <0.001 <0.001 0.04 (0.206) 
Potato (g/d) 103 (46) 102 (46) 0.040 <0.001 0.01 (0.695) 
Legumes (g/d) 17 (0.4) 18 (0.4) 0.270 <0.001 0.04 (0.906) 
Dairy (g/d) 393 (10) 346 (10) <0.001 <0.001 -0.15 (<0.001) 
  Whole milk (g/d) 37 (117) 35 (101) 0.222 <0.001 -0.01 (0.705) 
   Semi-skimmed milk (g/d) 142 (201) 112 (161) 0.009 <0.001 -0.08 (0.022) 
   Skimmed milk (g/d) 93 (160) 78 (149) 0.137 0.017 -0.05 (0.110) 
   Cheeses (g/d) 16 (169) 17 (17) 0.028 <0.001 0.03 (0.388) 
   Fresh cheese (g/d) 12 (19) 8 (13) <0.001 <0.001 -0.11 (0.001) 
Meat (g/d) 142 (2.8) 148 (3) <0.001 <0.001 0.06 (0.055) 
   Red meat (g/d) 82 (49) 88 (49) <0.001 <0.001 0.10 (0.003) 
   White meat (g/d) 59 (32) 59 (32) 0.989 <0.001 -0.02 (0.502) 
Fish (g/d) 103 (2) 101 (8) 0.054 <0.001 -0.05 (0.147) 
   White fish (g/d) 43 (27) 43 (26) 0.520 <0.001 -0.02 (0.440) 
    Fatty fish (g/d) 24 (20) 20 (18) 0.012 <0.001 -0.08 (0.018) 
Nuts (g/d) 8 (9) 6 (8) <0.001 <0.001 -0.12 (<0.001) 
Olive oil (g/d) 40 (0.9) 42 (0.8) 0.079 <0.001 0.05 (0.139) 
Jams (g/d) 0.8 (2) 1 (3) 0.549 <0.001 0.01 (0.583) 
Sugar (g/d) 4.5 (9) 5.8 (9.6) 0.021 <0.001 0.07 (0.031) 
Carbonated drinks (g/d) 12 (52) 17 (57) 0.073 <0.001 0.06 (0.076) 
Diet carbonated drinks (g/d) 19 (79) 26 (104) 0.200 0.441 0.02 (0.469) 
Micronutrients      
Marine Ω3 (g) 0.8 (0.02) 0.7 (0.02) 0.007 <0.001 -0.08 (0.015) 
No marine Ω3 (g) 1.5 (0.03) 1.4 (0.02) <0.001 <0.001 -0.06 (0.075) 
Ω 6 (g) 13.9 (0.2) 13.6 (0.6) <0.001 <0.001 -0.00 (0.882) 
Linoleic acid (g) 1.5 (0.6) 1.4 (0.4) <0.001 <0.001 -0.06 (0.065) 
Vit B1 (mg/d) 2.4 (0.8) 2.3 (0.8) 0.042 <0.001 -0.06 (0.062) 
Vit B6 (mg/d) 2.3 (0.6) 2.2 (0.5) <0.001 <0.001 -0.10 (0.002) 
Vit B12 (mg/d) 11 (5) 11 (6) 0.016 <0.001 -0.02 (0.540) 
Vit B2 (mg/d) 20 (0.5) 19 (0.5) <0.001 <0.001 -0.12 (<0.001) 
Vit C (mg/d) 189 (80) 173 (71) 0.009 <0.001 -0.11 (0.001) 
Vit E (µg /d) 10 (0.17) 10 (0.17) <0.001 <0.001 -0.05 (0.155) 
Vit D (µg /d) 6.2 (0.17) 5.5 (0.16) 0.001 <0.001 -0.08 (0.016) 
Folic Acid (µg /d) 391 (6) 364 (5) <0.001 <0.001 -0.13 (<0.001) 
Na (mg/d) 2608 (951) 2569 (937) <0.001 <0.001 -0.02 (0.565) 
K (mg/d) 4376 (1126) 4164 (1035) <0.001 <0.001 -0.09 (0.006) 
Fe (mg/d) 16 (4) 16 (4) <0.001 <0.001 -0.04 (0.210) 
Mg (mg/d) 380 (104) 362 (92) <0.001 <0.001 -0.10 (0.003) 
P (mg/d) 1769 (447) 1675 (409) <0.001 <0.001 -0.12 (<0.001) 
Ca (mg/d) 1080 (367) 999 (345) <0.001 <0.001 -0.13 (<0.001) 
Betacarotens (µg /d) 3438 (1923) 3076 (1994) 0.005 <0.001 -0.11 (0.001) 
Phytoesterols (mg/d) 350 (5) 338 (4.9) <0.001 <0.001 -0.053 (0.135) 
Score      
Dietary Inflammatory Index -0.7(0.07) -0.33 (0.07) <0.001 <0.001         0.139 (0.001) 
      
Continuous variables are shown as means ± SDs, and categorical variables are shown as 
percentages. P<0.05 was considered statistically significance. 
Panvoa1 was adjusted by BMI, gender and age. 
Panova2 was adjusted by BMI, gender, age, high adherence to MedDiet, smoking habit 
(dichotomous), hypertension (dichotomous), diabetes (dichotomous), hypercholesterolemia 
(dichotomous), alcohol intake (g/d), total energy intake (Kcal/d), physical activity (METS- h/d), 
waist circumference, and waist/height ratio. 
P50 FLI cut off value= 65.09  
 
Table 4 Analysis of linear regression model of association between Dietary 
Inflammatory Index and Fatty Liver Index in PREDIMED trial (n= 794). 
n= 794 β Std. Err. P [95% Conf. Interval] 
DII 3.057 0.590 <0.001 1.897     4.216 
Age (years) -0.503 0.132 <0.001 -0.763    -0.243 
Total energy intake 0.004 0.001 0.011 0.009     0.007 
Gender -2.699 1.627 0.012 -5.893    0.495 
ALT (U/L) 0.276 0.057 <0.001 0.164     0.389 
METs -0.579 0.189 0.002 -0.951    -0.208 
R
2
 adjusted 
P model 
   0.099 
<0.001      
P<0.05 was considered statistically significance 
 
 
 
 
